Home

Behzad Aghazadeh

CIK 1701815 · last filed 2022-06-17

Behzad Aghazadeh is a corporate insider who has filed 13 SEC Form 4 insider transactions across 3 companies since 2017. The most recent filing, for AADI, was dated Jun 17, 2022. Across all open-market trades the lifetime net is +$21.2M, making them a net buyer over the disclosed history. 43 SEC filings were submitted jointly with Avoro Capital Advisors LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

13

Lifetime Open-Market Net

$21.19M

Filer Profile

Reported Address
C/O AVORO CAPITAL ADVISORS LLC
110 GREENE STREET, SUITE 800
NEW YORK, NY 10012
Related Filers
Avoro Capital Advisors LLC — 43 joint filings, latest 2026-07-28
Avoro Ventures LLC — 13 joint filings, latest 2026-07-28
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Whitehawk Therapeutics, Inc. (AADI) Delisted Director 2,211,752 $2.05 $4.53M $0 2 2022-06-17
IMMUNOMEDICS INC (IMMU) Delisted Director 0 — — $73.48M 8 2020-10-23
Mirati Therapeutics, Inc. (MRTX) Delisted 10%+ Owner 4,111,281 $58.70 $241.33M -$52.30M 3 2019-02-21

Recent Filings

13 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-06-17 Whitehawk Therapeutics, Inc. (AADI) Delisted Grant (A) — $0 EDGAR
2021-08-30 Whitehawk Therapeutics, Inc. (AADI) Delisted Grant (A) +5,735,256 $75.00M EDGAR
2020-10-23 IMMUNOMEDICS INC (IMMU) Delisted Disp (D) −52,527,032 $0 EDGAR
2020-03-20 IMMUNOMEDICS INC (IMMU) Delisted Grant (A) +200,000 $0 EDGAR
2019-05-15 IMMUNOMEDICS INC (IMMU) Delisted Buy (P) +1,500,000 $22.66M EDGAR
2019-02-21 Mirati Therapeutics, Inc. (MRTX) Delisted Sell (S) −1,373,640 -$100.28M EDGAR
2018-06-19 IMMUNOMEDICS INC (IMMU) Delisted Buy (P) +400,000 $9.36M EDGAR
2018-06-15 IMMUNOMEDICS INC (IMMU) Delisted Buy (P) +1,150,000 $27.60M EDGAR
2018-06-12 Mirati Therapeutics, Inc. (MRTX) Delisted Buy (P) +800,000 $31.08M EDGAR
2017-11-16 Mirati Therapeutics, Inc. (MRTX) Delisted Mixed +1,375,000 $17.49M EDGAR
Showing 1–10 of 13
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.